Daito Pharmaceutical Co Ltd
TSE:4577

Watchlist Manager
Daito Pharmaceutical Co Ltd Logo
Daito Pharmaceutical Co Ltd
TSE:4577
Watchlist
Price: 2 009 JPY -0.79% Market Closed
Market Cap: 30.8B JPY
Have any thoughts about
Daito Pharmaceutical Co Ltd?
Write Note

Daito Pharmaceutical Co Ltd
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Daito Pharmaceutical Co Ltd
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Daito Pharmaceutical Co Ltd
TSE:4577
Capital Expenditures
-ÂĄ6.3B
CAGR 3-Years
0%
CAGR 5-Years
-11%
CAGR 10-Years
-10%
Takeda Pharmaceutical Co Ltd
TSE:4502
Capital Expenditures
-ÂĄ339.9B
CAGR 3-Years
-12%
CAGR 5-Years
-17%
CAGR 10-Years
-13%
Daiichi Sankyo Co Ltd
TSE:4568
Capital Expenditures
-ÂĄ169.7B
CAGR 3-Years
-42%
CAGR 5-Years
-20%
CAGR 10-Years
-12%
Otsuka Holdings Co Ltd
TSE:4578
Capital Expenditures
-ÂĄ141.7B
CAGR 3-Years
-26%
CAGR 5-Years
-14%
CAGR 10-Years
-7%
Chugai Pharmaceutical Co Ltd
TSE:4519
Capital Expenditures
-ÂĄ74.3B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
-15%
Astellas Pharma Inc
TSE:4503
Capital Expenditures
-ÂĄ76.4B
CAGR 3-Years
2%
CAGR 5-Years
-3%
CAGR 10-Years
-4%
No Stocks Found

Daito Pharmaceutical Co Ltd
Glance View

Market Cap
30.7B JPY
Industry
Pharmaceuticals

Daito Pharmaceutical Co., Ltd. engages in the development, production, and sale of pharmaceutical products. The company is headquartered in Toyama-Shi, Toyama-Ken and currently employs 846 full-time employees. The company went IPO on 2010-03-24. The pharmaceutical ingredients business is engaged in the manufacture, purchase, sale and entrusted manufacture business of pharmaceutical ingredients used as raw materials for pharmaceutical manufacture and formulation. The formulation business is engaged in the manufacture, purchase, sale and entrusted manufacture business of prescription pharmaceuticals and pharmaceuticals for general-use medicines.

Intrinsic Value
2 429.67 JPY
Undervaluation 17%
Intrinsic Value
Price

See Also

What is Daito Pharmaceutical Co Ltd's Capital Expenditures?
Capital Expenditures
-6.3B JPY

Based on the financial report for Aug 31, 2024, Daito Pharmaceutical Co Ltd's Capital Expenditures amounts to -6.3B JPY.

What is Daito Pharmaceutical Co Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-10%

Over the last year, the Capital Expenditures growth was -13%.

Back to Top